Learn About Relapsed Refractory Multiple Myeloma (RRMM)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Relapsed Refractory Multiple Myeloma (RRMM) Local Doctors?
Learn about our expert tiers
Learn more
What are the Latest Advances for Relapsed Refractory Multiple Myeloma (RRMM)?
Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma.
Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort.
Tired of the same old research?
Check Latest Advances
Daratumumab: A review of current indications and future directions.
What are the latest Relapsed Refractory Multiple Myeloma (RRMM) Clinical Trials?
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma

Summary: An open-label, Phase 1 study of HPN217 to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

Match to trials
Find the right clinical trials for you in under a minute
Get started
An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Multiple Myeloma (MM)

Summary: This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma